Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a…
Featured
-
-
Small biotechs shoulder the burdens of an uncertain biopharma sector
Recent US tariffs and federal funding cuts mean a heightened uncertainty for biopharma investors, and small biotechs are set to…
-
Caribou cuts pipeline and workforce to focus on lead CAR-T programmes
Caribou Biosciences is narrowing its pipeline and reducing its workforce by approximately 32% amid continued challenges in the cell and…
-
Trump order eases Medicare price negotiation for small molecule drugs
US President Donald Trump has issued a broad executive order to lower prescription drug prices in the country, notably including…
-
Can AI replace medical writers? Experts say not immediately
Artificial intelligence (AI) is said to be exponentially faster and effective at writing lengthy and complex clinical trial documents, but…
-
Streeting promises UK pharma quick action on VPAG frustration
The UK pharma industry can expect resolutions on a range of issues, including VPAG [Voluntary Scheme for Branded Medicines Pricing…
-
ABPI calls on UK Government to resolve “VPAG crisis”
Leaders of the Association of the British Pharmaceutical Industry (ABPI) say the UK Government must address rising clawback rates on…
-
UK life sciences venture capital funding lags behind
In 2024, life sciences was the only tech sector analysed where the UK had not improved its global share of…
-
Saving shelved ultra-rare therapies through unorthodox funding
As a funding drought for biopharma is on the horizon, non-profit biotech Orphan Therapeutics Accelerator is championing an innovative funding…
-
EU Health Data Space strikes a chord in EU harmonisation plans
Amidst a wave of regulatory changes in the European Union (EU) that are underway, the new EU Health Data Space…
